LIBerate-HeFH: Lerodalcibep reduces LDL-C in HeFH ORION-8: Inclisiran shows efficacy and safety beyond six years Phase 3 data show benefits of alirocumab in children with HeFH REMAIN-1: Recaticimab significantly reduces LDL-C even with infrequent dosing Phase 3 programme for MK-0616 gets underway MK-0616 – How near is an oral PCSK9i?

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Question of the Month

Combination therapy in familial hypercholesterolaemia: what can we gain from novel agents?

LDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?
Professor John Chapman

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »

News from the Trials

Keep up to date with latest news and analyses from PCSK9 inhibitor trials.

View latest news »

Trial Resources

For expert analysis and insights

View Trials »

View Trial slide decks »

Most viewed

ORION-8: Inclisiran shows efficacy and safety beyond six years Introducing another PCSK9 inhibitor – recaticimab REMAIN-1: Recaticimab significantly reduces LDL-C even with infrequent dosing PLEASe NEW Complementary slide resources… SANTORINI data support PCSK9i combinations for high risk patients CHORD EAS answers questions on Lp(a) consensus statement

Most viewed

ORION-8: Inclisiran shows efficacy and safety beyond six years

Hot Topics

18th Virtual Closed Scientific Expert Meeting of the Editorial Board

Statins and PCSK9 inhibitors in combination: Initial therapy in very high-risk patients in secondary prevention
Professor Alberto Zambon proposes a novel ‘fast to target’ paradigm for patients at very high cardiovascular risk.

Watch now

View all presentations »

From the Editors

MK-0616 - How near is an oral PCSK9i?

John chapman & Chris Packard Professors John Chapman and Chris Packard consider the evidence supporting MK-0616 as potentially the first oral PCSK9i to reach the clinic.